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a b s t r a c t
Background: With the introduction of mammography screening, we are more often dealing
with the diagnosis of precancerous and preinvasive breast lesions. An increasing number
of patients are observed to show a premalignant change of ADH (atypical ductal hyperpla-
sia). It also involves a wider use of the vacuum assisted core biopsy as a tool for verifying
nonpalpable changes identiﬁed by mammography.
Aim: This paper describes our experience of 134 cases of ADH diagnosed at Mammotome®
vacuum core needle biopsy.
Material and methods: Of 4326 mammotomic biopsies performed at our institution in
2000–2006, ADHwas diagnosed in 134 patients (3.1%). Patients underwent surgery to remove
the suspected lesion. All histopathological blocks were again reviewed by one pathologist.
Clinical, radiological and pathological data were collected for statistical evaluation.
Results: Underestimation of invasive changes occurred in 12 patients (9%). The only clin-
icopathologic feature of statistical signiﬁcance radiologically and pathologically was the
presence of radial scar in the mammography.
Conclusions: More frequent diagnosis of precancerous changes in the mammotomic breastbiopsy forces us to establish a clear clinical practice. The problem is the underestimation
of invasive changes. The occurrence of radial scar on mammography for diagnosis of the
presence of ADH increases the risk of invasive changes.
© 2012 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
changes, or if the area occupied by atypical cells is less than. Backgroundtypical ductal hyperplasia (ADH) is a premalignant change
n the breast. This change is detected when at least two lines
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or areas connected with the ducts are present by atypical cell48 618850600; fax: +48 618850601.
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two millimeters. Otherwise, we speak of DCIS (ductal carci-
noma in situ). It follows that the difference between ADH
and DCIS is minor, especially in the case of excision by core
. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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biopsy when we cannot visualize the entire area of a suspi-
cious change. This implies a great difﬁculty in putting the
ﬁnal diagnosis. Atypical ductal hyperplasia (ADH) of the breast
was ﬁrst described by Page in 1985 as an amendment to the
border between the ductal hyperplasia and ductal cancer in
situ (DCIS).1 Therefore, more and more suspicious nonpal-
pable changes of the breast discovered mammographically,
increased the frequency of mammotomic biopsies performed.
It has revolutionized the detection of early formsof breast can-
cer. Thus, screeningmammography andmammotomic biopsy
has contributed to the increased frequency of detection of
ADH. Nevertheless, mammotomic biopsy has its drawbacks
associatedwith the underestimation of invasive change in the
ﬁnal histological diagnosis.
In the case of diagnosis of ADH by core biopsy, it is nec-
essary to widen the resection of the change to the ﬁnal
pathologic examination. Known issue of underestimation of
lesions in the case of primary invasive diagnosis of ADH
applies up to 88% of cases when using 14G needles and
is reduced to a few percent if vacuum core needle biopsy
is used.2–8 With ADH diagnosed, the risk of breast cancer
increases 4–5 times. This risk is doubled if we are dealing
with a positive family history of breast cancer.9 Collins et al.
investigated a group of women undergoing core biopsy in
the Nurses’ Health Study, with atypical hyperplasia as the
most advanced change.10 The women with atypia (ADH and
ALH (atypical lobular hyperplasia)) were older, less frequently
premenopausal and nulliparous, compared with the control
group. Women with ADH drank slightly more alcohol, were
more likely tohaveundergonebilateral resectionof the ovaries
and a greater proportion of applied hormone replacement
therapy for longer than 5 years. In the Mayo Cohort Study,
women with atypia (ADH and ALH) showed a very high risk of
developing breast cancer (risk >50% over 20 years) in the event
ofmultiple foci of histologically found atypia and the presence
of microcalciﬁcations.11 In this group of patients, family his-
tory of breast cancer had no effect on increasing breast cancer
risk.
In the model of cancer cell lines from normal glandular
breast to invasive cancer have several stages until the prein-
vasive and invasive cancer.12 In the case of growth of normal
cells, we are talking about usual ductal hyperplasia (UDH).
In the case of accumulation of irregularities within the cell
nucleus,we can talk about the acquisition and the characteris-
tics of atypical histology that can be observed in ﬂat epithelial
atypia (FEA). A continued proliferation of this change is the
next stage of ADH. Then we have to deal with cancer, only
that it is separated from the basal membrane of normal cells
and thus qualiﬁed as DCIS. In the case of tumor cell invasion
through the basement membrane of DCIS initially taking with
microinvasive and then to invasive breast cancer.
2. AimThe aim is to evaluate the underestimation of the preinvasive
and invasive changes after an initial diagnosis of ADH using
mammotomic vacuum core needle biopsy.iotherapy 1 7 ( 2 0 1 2 ) 129–133
3. Materials and methods
We analyzed retrospectively 134 patients with a primary diag-
nosis of ADH on the basis of Mammotome 11G vacuum
assisted core needle biopsy.
A biopsy was performed in the outpatient mammotomic
unit at the Department of Surgical Oncology and General
Surgery I, Greater Poland Cancer Centre. For six and a half
years, 4326 biopsies have been performed. Biopsies were done
in patients with nonpalpable breast changes seen in mam-
mography. Patients who had undergone ultrasound guided
biopsy were excluded from this study. Mammotomic biopsy
was performed on the table, where patients were turned to
face downwards (Fisher Imaging, Denver, CO, USA) using an
11G directional vacuum assisted biopsy system (Mammo-
tome; Biopsy/Ethicon Endo-Surgery, Cinncinatti, Ohio). We
obtained an average of 12 cores (from 7 to 30). In case of ADH,
all patients were admitted for surgical resection of the breast
area where ADH was found. For all cases, images and descrip-
tions of mammography, or ultrasound data were collected for
review.Themedical historieswere re-examinedandveriﬁed in
terms of clinical data such as age, data on the patient’s onco-
logical history, family burden, mammographic presentation,
concomitant benign lesions of the breast, type of operation.
The size of the breast change was not identiﬁed. All patholog-
ical slides were again reviewed by one pathologist (PK).
Collected clinical parameters, as well as radiological and
pathological ﬁndings were statistically analyzed to determine
differences in study groups or the relationship between the
measured traits.
All tests were analyzed at the signiﬁcance level ˛=0.05. For
statistical analysis statistical package Statistica 8.0 (StatSoft
Inc.) was used.
4. Results
Underestimation of invasive changes occurred in 12 patients
(9%). Age of patients diagnosed with ADH without cancer in
ﬁnal pathology was 55.6 and for patients with underestima-
tion of cancer 60.7. When dividing patients into 2 groups (less
or equal to 60 years and more than 60 years), no signiﬁcant
difference in ADH proportions was observed. But analyzing
groups with and without underestimation, a signiﬁcance was
observed p=0.0349. Patients with underestimation were on
average older than those without underestimation.
There was a signiﬁcant difference in the frequency of dif-
ferent diagnoses, mammography, depending on ﬁnal changes
to non-invasive diagnosis and under-invasive changes
(p=0.0001).
Radial scar is more common in the evolution of inva-
sive breast screening andother diagnoses (microcalciﬁcations,
macrocalciﬁcations,mass anddensity) aremore characteristic
for non-invasive change (Table 1).
Among patients diagnosed with ADH on the basis of
Mammotome biopsy, there were no statistically signiﬁcant
differences in the incidence of various histopathological fac-
tors in breast glands, depending on the invasiveness of the
change. We analyzed such changes as the CCC (columnare
reports of practical oncology and radio
Table 1 – Underestimation of cancer in comparison with
mammographical manifestation of the ADH during
biopsy.
Mammographical
picture
Noninvasive
change, n=122
Underestimation
of invasive
cancer, n=12
Microcalciﬁcations 93 (76.9%) 4 (33.3%)
Macrocalciﬁcations 0 1 (8.3%)
Tumor mass 17 (14.1%) 1 (8.3%)
Radial scar 6 (5%) 5 (41.7%)
Density 5 (4.1%) 1 (8.3%)
c
d
m
a
u
A
e
5
M
p
s
c
T
a
A
d
e
t
U
c
o
t
V
i
a
change <6mm with incomplete resection of microcalciﬁca-Statistical importance proved by Fisher–Freeman–Halton test:
p=0.0001.
ell changes), CCH (columnare cell hyperplasia), UDH (usual
uctal hyperplasia), adenosis simplex, adenosis sclerosans,
icrocalciﬁcations, mastopathy (Table 2).
Additionally, no statistical signiﬁcance was observed
ccording to breast side, and accurate position in the breast
sing quadrants. Analyzing numbers of foci in both groups in
DH only the mean number of foci was 2.53 and in the under-
stimated one 3.55. No statistical signiﬁcance was observed.
. Conclusions
ammotome biopsy of mammographically suspicious non-
alpable breast changes is associated with less morbidity and
horter hospital stay, lower cost compared with open surgi-
al biopsy, which used to be a standard practice in the past.
he frequency of detection of ADH by core needle biopsy is,
ccording to different authors, from 2 to 11%.13,14 In our study,
DH was diagnosed in 134 patients, representing 3.1% of the
iagnoses made on the basis of Mammotome® biopsy. In the
arly studies of underestimation of the changes after the ini-
ial biopsy, 14G AGCB (automated gun core biopsy) was used.
nfortunately, this resulted in underestimation of invasive
hange in the limits of 17–88%, on average 44%.2–8 In the case
f 14G VACB (vacuum assisted core biopsy) average underes-
imation of the tumor decreased to 24%.15 Currently, the 11G
ACB is performed. With this device, the underestimation of
nvasive changeswas reduced to the value from 0 to 38%, aver-
ge 19%.5,16 In our study, it amounted to 9%. The desirability
Table 2 – Underestimation of invasive cancer in comparison wi
ADH during biopsy.
Concomitant
changes
diagnosed with
ADH on biopsy
Noninvasive
change, n=122
CCH 11 (9%)
CCC 6 (4.9%)
UDH 43 (35.3%)
Adenosis simplex 11 (9%)
Mastopatia 74 (60.6%)
Mikrozwapnienia 98 (80.3%)
Adenosis sclerosans 69 (56.6%)
Lipomatosis 18 (14.8%)
Fibroadenoma 8 (6.56%)therapy 1 7 ( 2 0 1 2 ) 129–133 131
of a subsequent operation in all cases is being discussed.
Researchers are looking for predictors of co-occurrence inADH
of DCIS or invasive changes. According to Liberman et al., the
most common image of ADH in the mammogram are clus-
tered microcalciﬁcations.17 They could not, however, identify
the characteristics associated with the interaction of invasive
changes. According to Ely et al., the factor associated with an
increased incidence of DCIS or IDC is the presence of≥4 foci of
ADH, or cases with the presence ofmicropapillary ADH only.15
With ≤2 foci of ADH and a complete removal of suspicious
mammographic changes, there appeared to be no need for
surgical resection. Gombos et al. propose using immunohis-
tochemistry for the evaluation of core biopsy ADH.18 Lack of
CK 34 beta E12 was associated with the presence of atypia in
hyperplasia inside theduct. Libermanet al. stresses the impor-
tance of total excision biopsy of the lesions rather than just
sampling for pathological examination.7 Thanks to this proce-
dure the underestimation of the incidence of invasive changes
is reduced. In this study, the complete removal of the lesions
with the VACB resulted in the underestimation was 18.8%.
When the specimens were only partially collected from the
lesions, the underestimation was 31.3%. The review paper by
Jacobs et al. proposed, in the case ofmicro-histological diagno-
sis ofADH, a limited extent of total lesion resectionduring core
biopsy when there are no indications for surgical removal.19
In the study by Forgeard et al. a group of 300 patients with
a diagnosis of ADH in 11G Mammotome biopsy was divided
into a subgroup of patients undergoing surgical resection (116
patients – 39%) and oncological observation (184 patients –
61%).20 Patients were divided according to the risk of cancer
presence into 3 groups. First, without an underestimation of
the tumor in case of change of diameter <6mm complete the
removal by the Mammotome biopsy. The second group of low
underestimation of concomitant tumor (4%) in the presence of
≤2 foci of ADH in the area of microcalciﬁcations with concur-
rent changes in diameter <6mm and the incomplete removal
or ≥6mm and <21mm. The third group of patients at high
risk of concomitant cancer – 36–38% of the tumor in the pres-
ence of >2 foci of ADH in microcalciﬁcations and diametertions, or ≥6mm and <21mm with complete and incomplete
removal ofmicrocalciﬁcations, or the size of changes≥21mm.
The averagenumber of coreswas 16,with 11.5 in other studies,
th concomitant benign changes diagnosed together with
Underestimation
of invasive cancer,
n=12
p value
1 (8.3%) 0.94
0 0.43
5 (50%) 0.58
0 0.28
5 (41.7%) 0.2
8 (66.7%) 0.27
7 (58.3%) 0.9
0 0.15
0 0.36
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also the rate of change was 2 times higher than in comparable
publications.
The study group in Plantade et al. diagnosed with ADHwas
divided into those requiring surgical resection and those sub-
jected to intensive follow-up.21 The indication for surgery was
breast cancer (or family history), lesion size >10mm, the pres-
ence of ADH in the last deleted core tissue and concomitant
LN (lobular neoplasia). Ely et al. study of 46 patients demon-
strated relation between the underestimation of tumor and
extent of ADH.15 When this change concerned a 2 or fewer foci
of ADH no other concomitant change was observed, whereas
in the presence of 3 or 4 foci of ADH, the underestimation
of DCIS/invasive cancer reached 50 and 87%. The authors did
not recommend surgical resection in the presence of 2 and
fewer foci of ADH. Sneige et al. give 3 or less ADH lesions after
total resection of the ADH lesions as a value where no further
concomitant preinvasive or invasive changes were seen.22
Currently, stereotactic core needle biopsy under mam-
mographical guidance is a standard diagnostic tool in
examination of non-palpable breast lesions.We presented our
experience in the group of clinico-pathological challenges in
case of diagnosis by core needle biopsy of a premalignant or
preinvasive change in previous papers.23–26 Selected clinical
factors, radiological and pathological, can be used to assess
the risk of invasive changes coexistence. The occurrence of
radial scar on mammography for diagnosis of the presence of
ADH increases the risk of invasive changes. Additionally we
should also think about better information for patients as well
as support especially in case of increased risk of breast cancer
in the future.27,28
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